Early stroke and systemic embolism rates in patients following cardioversion for atrial fibrillation (A-fib) are low and comparable between those receiving warfarin or the novel oral anticoagulant ...

But the current study, from Dr Gaetano M De Ferrari (University of Pavia, Italy) and colleagues, suggests that there can be a role for cardioversion in some populations, in this case patients with ...

Introduction: There is insufficient evidence on the efficacy and safety of pharmacological cardioversion of recent-onset atrial fibrillation (AF) in elderly patients. Antazoline has been shown to be ...

The conventional treatment strategy for patients with atrial fibrillation who are to undergo electrical cardioversion is to prescribe warfarin for anticoagulation for three weeks before cardioversion.

LISBON, Portugal—Patients presenting to the emergency department (ED) with new, symptomatic A-fib do not necessarily need to undergo immediate cardioversion, as is now common practice, the RACE 7 ...

Warfarin, dabigatran and rivaroxaban are safe periprocedural anticoagulation options for patients undergoing cardioversion or ablation for atrial fibrillation, according to researchers in Canada. “We ...

Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — Patients with nonvalvular atrial fibrillation undergoing elective cardioversion who were ...

The 2006 American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) Practice Guidelines for the Management of Atrial Fibrillation state that various benign ...

In the TEE (+) group, LAAT was observed in 26 patients (7.18%). None of the patients had a thromboembolic event within the first month of follow-up. In this observational study, we investigated ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...